200
Participants
Start Date
May 30, 2023
Primary Completion Date
January 16, 2025
Study Completion Date
January 16, 2025
Semaglutide
Participants will receive semaglutide tablets orally once daily for 44 weeks.
Semaglutide Placebo
Participants will receive placebo matched to semaglutide.
Peking University People's Hospital-Endocrinology, Beijing
Beijing Friendship Hospital, Capital Medical University-Endocrinology, Beijing
Huashan Hospital Fudan University-Endocrinology, Shanghai
Shanghai Pudong New Area People's Hospital-Endocrinology, Shanghai
The Second Affiliated Hospital of Nanjing Medical University, Nanjing
The Affiliated Hospital of Jiangsu University, Zhenjiang
Changzhou No.2 People's Hospital, Changzhou
Jinan Central Hospital, Ji'nan
General Hospital of Tianjin Medical University-Endocrinology, Tianjin
Chongqing University Three Gorges Hospital, Chongqing
The First People's Hospital of Changde City-Endocrinology, Changde
Taihe Hospital, Shiyan
The First Affiliated Hospital of Henan University of science and Technology, Luoyang
Huaihe Hospital of Henan University-Endocrinology, Kaifeng
Huizhou Central People's Hospital-Endocrinology, Huizhou
Lead Sponsor
Novo Nordisk A/S
INDUSTRY